Core Insights - The 2025 Second Jiamusi "China Dental City" High-Quality Development Conference aims to enhance the city's profile in the Northeast Asia dental industry [1] - Jiamusi is committed to building a "China Dental City" with a solid foundation, platform, potential, and support [2] Industry Development - The oral care market in China is growing steadily at a compound annual growth rate of 10%, expected to exceed 100 billion yuan by 2025 [2] - Jiamusi occupies over one-third of the provincial dental service market, with denture production capacity accounting for more than one-fourth of the province's total [2] Innovation and Education - Jiamusi University School of Stomatology has trained over 10,000 graduates, including more than 1,000 master's degree holders, contributing to the local dental industry's innovation [3] - The establishment of the "China Dental City" strategy in 2022 aims to leverage local strengths in dental education, medical services, and denture manufacturing [3] Project Development - In the previous year's conference, 30 projects were signed with a total investment of 1.275 billion yuan, and new enterprises are continuing to settle in Jiamusi [4] - The establishment of a modern production base for high-end medical products is underway, with projected annual sales exceeding 100 million yuan [4] Technological Advancements - The conference showcased cutting-edge technologies, including a dental implant navigation device that enhances surgical precision and efficiency [6] - Innovations in dental equipment are moving towards smart and digital solutions, improving treatment accuracy and patient comfort [6][7] Future Outlook - The construction of "China Dental City" is accelerating, with more expert teams and projects expected to invigorate the Northeast Asia dental industry [7]

Core Viewpoint - The company reported a decline in revenue for 2024, primarily due to price reductions in biochemical reagents resulting from domestic IVD centralized procurement, but managed to achieve a slight increase in net profit, indicating effective cost control [3][4]. Financial Performance - In 2024, the company achieved total revenue of 1.659 billion yuan, a year-on-year decrease of 4.75% - The net profit attributable to shareholders was 533 million yuan, reflecting a year-on-year increase of 1.70% - The net profit excluding non-recurring items was 521 million yuan, up 1.93% year-on-year - In Q4 2024, the company reported a single-quarter revenue of 422 million yuan, down 17.01% year-on-year, while the net profit attributable to shareholders was 159 million yuan, an increase of 4.48% [3][4]. Operational Insights - The company's revenue decline was mainly influenced by the significant drop in biochemical reagent prices due to centralized procurement, which exerted pressure on the biochemical business line - Despite the revenue decline, the net profit showed a quarter-on-quarter increase of 29.5% in Q4, indicating improving profitability [4]. R&D and Product Development - The company has increased its R&D investment, with a research and development expense ratio of 11.36% in 2024, up 2.01 percentage points year-on-year - By the end of 2024, the company obtained 379 medical device registration certificates, up from 294 at the end of 2023, covering various fields including biochemistry, coagulation, chemiluminescence, blood typing, and POCT - The company also added 19 new patents and received approvals for multiple pathology, biochemistry, coagulation, and chemiluminescence reagent products, enhancing its product portfolio [5]. Strategic Initiatives - The subsidiary, Mai Xin Bio, is focusing on core technologies in pathological diagnosis and is expanding into areas such as companion diagnostics and pathology AI - Mai Xin Bio is also actively pursuing international markets, working on product qualification in mature markets like Europe and the US, as well as emerging markets in the Middle East and Southeast Asia, thereby entering a new phase of internationalization [6].